Significantly improved upper gastrointestinal (UGI) telerability with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I trial

✍ Scribed by Jay L. Goldstein; Naurang Agrawal; Glenn M. Eisen; William Stenson; Al E. Bello; John G. Fort; Susan P. Boots

• Book ID: 119429380
• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 176 KB
• Volume: 120
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/s0016-5085(08)80516-1